Lenders
When a software credit turns, you already have the seats covered that can be covered. The financial advisor builds the 13-week cash flow. The banker tells you the market’s mood. A CRO, if it comes to that, runs the company. But a 13-week cash flow tells you how long the company can wait; it does not tell you what it will recover. Nobody at the table tells you what a buyer’s diligence will find, what each defect costs in enterprise value, and which recovery the credit can actually support. Most lenders never get that question answered until a process fails. That is the seat we fill. The seat is the same in a bank’s special assets group; what differs is the approval chain, which is why the way in is staged: each step is a bounded decision, priced on its own, cleared before the next is asked for.
Best recovery is yours to define, and every engagement starts with your objective and reports against it. The economics follow the work, and are agreed before it starts.
The way in is staged, and each stage earns the next: the portfolio watch across the book with no name designated and nothing signaled, the first read on one name, then exit underwriting where the evidence says it should follow, prepared under the seat you elected. The stages, in full.
Two things we hold to throughout. We work with the sponsor, not around them: a prepared sale clears above the as-is case for their equity as well as your claim. And information walls are agreed in writing before we see anything. The credit-side habits of the partners who built this screen from your side of the table, at direct-lending and credit funds, are the habits it runs on.
Start with the portfolio watch, or a first read on one name. No name is designated.